A citation-based method for searching scientific literature

Aránzazu Lafuente-Sanchis, Ángel Zúñiga, Miriam Estors, Néstor J Martínez-Hernández, Antonio Cremades, María Cuenca, José M Galbis. Clin Lung Cancer 2017
Times Cited: 20







List of co-cited articles
92 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
30

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
25

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
25

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
F Stephen Hodi, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth F Grossmann, David F McDermott, Gerald P Linette, Nicolas Meyer, Jeffrey K Giguere, Sanjiv S Agarwala,[...]. Lancet Oncol 2016
565
20

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
20

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
20

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, David Smith, Angel Artal-Cortes, Conrad Lewanski,[...]. Lancet 2016
20

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
20

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
20

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Zoran Gatalica, Carrie Snyder, Todd Maney, Anatole Ghazalpour, Daniel A Holterman, Nianqing Xiao, Peggy Overberg, Inga Rose, Gargi D Basu, Semir Vranic,[...]. Cancer Epidemiol Biomarkers Prev 2014
324
20

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Tanguy Y Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph Paul Eder, Karl Heath, Terrill McClanahan, Jared Lunceford, Christine Gause,[...]. Lancet Oncol 2016
938
15

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
15

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
15

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even,[...]. N Engl J Med 2016
15

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, John D Powderly,[...]. J Clin Oncol 2014
15

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
15

Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Jong-Mu Sun, Wei Zhou, Yoon-La Choi, So-Jung Choi, Se Eun Kim, Zhen Wang, Marisa Dolled-Filhart, Kenneth Emancipator, Dianna Wu, Russell Weiner,[...]. J Thorac Oncol 2016
113
15

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, Adil Daud, F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D Wolchok, Peter Hersey, Richard W Joseph, Jeffrey S Weber,[...]. N Engl J Med 2013
15

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
R Houston Thompson, Haidong Dong, Christine M Lohse, Bradley C Leibovich, Michael L Blute, John C Cheville, Eugene D Kwon. Clin Cancer Res 2007
410
15

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Silvia Darb-Esfahani, Catarina Alisa Kunze, Hagen Kulbe, Jalid Sehouli, Stephan Wienert, Judith Lindner, Jan Budczies, Michael Bockmayr, Manfred Dietel, Carsten Denkert,[...]. Oncotarget 2016
164
15


Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
15

MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.
Patrizia Leone, Eui-Cheol Shin, Federico Perosa, Angelo Vacca, Franco Dammacco, Vito Racanelli. J Natl Cancer Inst 2013
283
15

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.
Mark A Perazella, Anushree C Shirali. J Am Soc Nephrol 2018
69
15

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, Nagahiro Minato. Proc Natl Acad Sci U S A 2002
15



Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
S A Rosenberg, M T Lotze, J C Yang, P M Aebersold, W M Linehan, C A Seipp, D E White. Ann Surg 1989
990
10

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O'Day, Jeffrey Weber, Claus Garbe, Celeste Lebbe, Jean-François Baurain, Alessandro Testori, Jean-Jacques Grob,[...]. N Engl J Med 2011
10

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, Thomas Powles, Daniel P Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia,[...]. Lancet 2017
10

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
10

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
10

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll. Nat Rev Cancer 2016
10

Immunologic correlates of the abscopal effect in a patient with melanoma.
Michael A Postow, Margaret K Callahan, Christopher A Barker, Yoshiya Yamada, Jianda Yuan, Shigehisa Kitano, Zhenyu Mu, Teresa Rasalan, Matthew Adamow, Erika Ritter,[...]. N Engl J Med 2012
10

T-cell regulation by CD28 and CTLA-4.
M L Alegre, K A Frauwirth, C B Thompson. Nat Rev Immunol 2001
577
10

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Steven A Rosenberg, James C Yang, Richard M Sherry, Udai S Kammula, Marybeth S Hughes, Giao Q Phan, Deborah E Citrin, Nicholas P Restifo, Paul F Robbins, John R Wunderlich,[...]. Clin Cancer Res 2011
10

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
662
10

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
William D Travis, Elisabeth Brambilla, Andrew G Nicholson, Yasushi Yatabe, John H M Austin, Mary Beth Beasley, Lucian R Chirieac, Sanja Dacic, Edwina Duhig, Douglas B Flieder,[...]. J Thorac Oncol 2015
10


PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Wendy A Cooper, Thang Tran, Ricardo E Vilain, Jason Madore, Christina I Selinger, Maija Kohonen-Corish, PoYee Yip, Bing Yu, Sandra A O'Toole, Brian C McCaughan,[...]. Lung Cancer 2015
200
10

High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Yih-Leong Chang, Ching-Yao Yang, Yen-Lin Huang, Chen-Tu Wu, Pan-Chyr Yang. Oncotarget 2017
39
10

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Shafei Wu, Xiaohua Shi, Jian Sun, Yuanyuan Liu, Yufeng Luo, Zhiyong Liang, Jinghui Wang, Xuan Zeng. Oncotarget 2017
44
10

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
Jun Konishi, Koichi Yamazaki, Miyuki Azuma, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Masaharu Nishimura. Clin Cancer Res 2004
550
10

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
A D'Incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, C Tibaldi, G Minuti, J Salvini, E Coppi,[...]. Br J Cancer 2015
402
10

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Deepa Rangachari, Paul A VanderLaan, Meghan Shea, Xiuning Le, Mark S Huberman, Susumu S Kobayashi, Daniel B Costa. J Thorac Oncol 2017
93
10

PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.
Shenyou Sun, Xiaochun Fei, Yan Mao, Xiumin Wang, David H Garfield, Ou Huang, Jinglong Wang, Fei Yuan, Long Sun, Qixiang Yu,[...]. Cancer Immunol Immunother 2014
100
10

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
10

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
10


Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Jayanta Chatterjee, Wei Dai, Nor Haslinda Abd Aziz, Pei Yun Teo, John Wahba, David L Phelps, Christian J Maine, Lynsey M Whilding, Roberto Dina, Giorgia Trevisan,[...]. Clin Cancer Res 2017
38
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.